Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
Yuan Jiang, Yue Li, Larry X. W. Wang
Topics & Concepts
MedicineNivolumabChemotherapyOncologyInternal medicineCancerCost effectivenessClinical trialCost-effectiveness analysisQuality-adjusted life yearEsophageal cancerImmunotherapyRisk analysis (engineering)Gastric Cancer Management and OutcomesEsophageal Cancer Research and TreatmentCancer Immunotherapy and Biomarkers